Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 02, 2007. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically detailing share allocations for Non-Executive Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding director share interests rather than a financial performance report.
Material Changes
On December 31, 2006, the Company's Non-Executive Directors were provisionally allocated awards over Ordinary Shares and American Depository Shares (ADSs) under share allocation arrangements for the service period from October 1, 2006, to December 31, 2006. The Company and the directors were informed of these allocations on January 2, 2007.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of director share transactions in accordance with Disclosure Rule 3.1.4R(1)(b).
Important Facts for Investors
- The filing discloses provisional share awards for Non-Executive Directors for the Q4 2006 service period.
- Allocations were made in both Ordinary Shares and American Depository Shares (ADSs).
- Specific allocations included 1,861.50 shares/ADSs for Sir Christopher Gent and 689.96 for Mr Lawrence Culp, among others.
- No financial performance data or strategic outlook is contained in this specific filing.